{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:40:16Z","timestamp":1793608816147,"version":"4.5.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Nonalcoholic fatty liver disease (NAFLD) is a liver disorder commonly associated with metabolic syndrome and cardiovascular disease (CVD). Atherosclerosis, a leading cause of CVD, has been linked to liver fibrosis. However, the evidence regarding this association is conflicting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the link between liver fibrosis and subclinical atherosclerosis in patients with NAFLD<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a comprehensive search of four databases from 1950 to February 2023 to identify eligible studies investigating the association between liver fibrosis and subclinical atherosclerosis among patients with NAFLD, utilising the PICOS framework. Two independent reviewers screened the studies; quality was assessed using the Newcastle\u2010Ottawa Scale. Meta\u2010analysis was performed using the DerSimonian\u2010Liard random\u2010effects model, and subgroup analysis was conducted based on the severity of liver fibrosis, type of subclinical atherosclerosis diagnosis and geographic region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The meta\u2010analysis included 12 studies with a total of 4725 patients. Overall pooled odds ratio (OR) for subclinical atherosclerosis was 2.18 (95% CI: 1.62\u20132.93), indicating a significant association with liver fibrosis in NAFLD. Subgroup analysis revealed higher ORs in patients with more severe fibrosis: 1.64 (95% CI: 1.22\u20132.20) in \u2265F1, 2.22 (95% CI: 1.37\u20133.62) in \u2265F2, and 3.42 (95% CI: 1.81\u20136.46) in \u2265F3. However, there was no significant difference between the West versus East and various measurements of subclinical atherosclerosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Any degree of fibrosis is significantly associated with subclinical atherosclerosis, with fibrosis severity amplifying the association.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.17617","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T16:30:18Z","timestamp":1687624218000},"page":"384-394","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Systematic review and meta\u2010analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease"],"prefix":"10.1111","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-9989","authenticated-orcid":false,"given":"Mohamad","family":"Jamalinia","sequence":"first","affiliation":[{"name":"Gastroenterohepatology Research Center Shiraz University of Medical Sciences  Shiraz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Zare","sequence":"additional","affiliation":[{"name":"Gastroenterohepatology Research Center Shiraz University of Medical Sciences  Shiraz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran B.","family":"Lankarani","sequence":"additional","affiliation":[{"name":"Health Policy Research Center Institute of Health, Shiraz University of Medical Sciences  Shiraz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.013"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10146"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0014-9"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25593"},{"key":"e_1_2_8_9_1","first-page":"1063A","article-title":"Arterial stiffness is independently associated with liver stiffness in biopsy\u2010proven non\u2010alcoholic fatty liver disease: a transient elastography study","volume":"70","author":"Bilgin B\u00d6","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.5455\/gulhane.39850"},{"key":"e_1_2_8_11_1","first-page":"A584","article-title":"In obese and type 2 diabetic patients, hepatic fibrosis is associated with increased artery stiffness","volume":"59","author":"Jaber Y","year":"2010","journal-title":"Diabetes"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.06.801"},{"key":"e_1_2_8_13_1","first-page":"S100","article-title":"Subclinical atherosclerosis in non\u2010alcoholic fatty liver disease with advanced fibrosis \u2010 is metabolic syndrome the mediator?","volume":"41","author":"Pal R","year":"2022","journal-title":"Indian J Gastroenterol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_2_8_15_1","volume-title":"The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses.","author":"Wells GA","year":"2014"},{"key":"e_1_2_8_16_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins J","year":"2022"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn065"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840200104"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.05.059"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95581-8"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224184"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10108-z"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.003"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16324"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.15557\/JoU.2018.0044"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05926-7"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002375"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12114"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12992"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023360"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000504"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000909"},{"issue":"3","key":"e_1_2_8_33_1","first-page":"196","article-title":"Association of non\u2010alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta\u2010analysis","volume":"16","author":"Koulaouzidis G","year":"2021","journal-title":"Prz Gastroenterol"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001850"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.17617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T02:42:54Z","timestamp":1692326574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.17617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/apt.17617"],"URL":"https:\/\/doi.org\/10.1111\/apt.17617","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"2023-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}